Cardiovascular Risks of Adderall and Alcohol Combination

Introduction to Risks

The American Heart Association and American College of Cardiology identify amphetamines, including Adderall, as substances with adverse cardiovascular effects, including stimulation of the sympathetic nervous system, increased blood pressure, and tachycardia 1, 2

Amphetamines directly stimulate adrenergic receptors and cause release of dopamine and norepinephrine, resulting in increased blood pressure, with an average increase of 1-4 mm Hg, but 5-15% of patients experience substantially higher increases 3, 4
The American Heart Association recommends limiting caffeine intake to less than 200mg per day when taking amphetamines, as vasoconstrictive substances exacerbate cardiovascular effects 5

The 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guidelines state that amphetamines have adverse cardiovascular effects and potential for drug-drug interactions 1, 2
The Canadian Stroke Best Practice guidelines recommend that individuals with stroke and known recreational drug use of amphetamines should discontinue use and receive appropriate support 6
Both methylphenidate and amphetamines should be avoided in patients with uncontrolled hypertension, coronary artery disease, or tachyarrhythmias 4

Patients taking Adderall should be counseled to avoid alcohol entirely, and obtain history of cardiac symptoms and family history of cardiovascular conditions before initiating Adderall 3
Monitor vital signs regularly, as blood pressure and heart rate changes indicate severity of systemic vasoconstriction 5
Patients should be warned about the risks of combining Adderall with any vasoconstrictive substances, including alcohol 5

Individuals with personal or family history of cardiac conditions are at higher risk 4
Patients with history of migraine, Raynaud's phenomenon, or other vasospastic disorders are at higher risk 5
Those with pre-existing cardiovascular conditions may experience more severe manifestations 5
Higher doses of Adderall substantially increase cardiovascular risk 3